Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development

Lead Product(s): Brincidofovir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection.

Lead Product(s): Ridinilazole

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority

Deal Size: $72.5 million Upfront Cash: Undisclosed

Deal Type: Funding January 23, 2020

Details:

The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million.

Lead Product(s): Cantharidin

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 18, 2020

Details:

Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive

Lead Product(s): Recombinant quadrivalent seasonal influenza vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2020

Details:

The ongoing Phase 3 clinical trial is intended to evaluate the immunogenicity and safety of NanoFlu compared to the quadrivalent formulation of Fluzone.

Lead Product(s): Fostemsavir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

This application seeks approval of fostemsavir, used in combination with other antiretrovirals, for the treatment of adults with multidrug-resistant HIV-1 infection.

Lead Product(s): Exebacase

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the U.S. to assess the efficacy and safety of exebacase in 350 patients.

Lead Product(s): Sci-B-Vac

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

The Phase 3 study, met both the primary and secondary endpoints. Sci-B-Vac achieved seroprotection rates of 99.3% and 90.4% after 3 and 2 doses, respectively, compared with 94.8% and 51.6% with Engerix.

Lead Product(s): CRM197

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Serum Institute of India Private Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 08, 2020

Details:

Pfenex is eligible to receive annual fees, milestone payments, and royalty based on net sales for all products developed by Serum Institute that use the CRM197 produced via Pfenex Expression Technology.

Lead Product(s): Micafungin

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable